Haemonetics Corporation (HAE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
HAE Revenue Growth
Revenue Breakdown (FY 2025)
HAE's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
HAE Revenue Analysis (2014–2025)
As of May 6, 2026, Haemonetics Corporation (HAE) generated trailing twelve-month (TTM) revenue of $1.32 billion, reflecting slight decline in growth of -2.7% year-over-year. The most recent quarter (Q3 2026) recorded $339.0 million in revenue, up 3.6% sequentially.
Looking at the longer-term picture, HAE's 5-year compound annual growth rate (CAGR) stands at +6.6%, indicating steady revenue expansion. The company achieved its highest annual revenue of $1.36 billion in 2025, representing a new all-time high.
Revenue diversification analysis shows HAE's business is primarily driven by Hospital (41%), Plasma (39%), and Blood Center (19%).
When compared to Healthcare sector peers including TFX (-2.7% YoY), HOLX (+2.2% YoY), and ITGR (+6.0% YoY), HAE has underperformed the peer group in terms of revenue growth. Compare HAE vs TFX →
HAE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| HAECurrent | $1.3B | -2.7% | +6.6% | 16.3% | |
 TFX | $2.0B | -2.7% | -4.7% | 12.8% | |
 HOLX | $4.1B | +2.2% | +1.7% | 17.4% | |
 ITGR | $1.8B | +6.0% | +11.5% | 11.3% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 NNOX | $11M | +15.2% | - | -502.9% |
HAE Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $1.36B | +4.0% | $778.5M | 57.2% | $221.8M | 16.3% |
| 2024 | $1.31B | +12.0% | $711.9M | 54.4% | $164.9M | 12.6% |
| 2023 | $1.17B | +17.7% | $622.9M | 53.3% | $156.0M | 13.4% |
| 2022 | $993.2M | +14.1% | $530.8M | 53.4% | $80.8M | 8.1% |
| 2021 | $870.5M | -11.9% | $428.4M | 49.2% | $89.7M | 10.3% |
| 2020 | $988.5M | +2.2% | $487.8M | 49.4% | $103.4M | 10.5% |
| 2019 | $967.6M | +7.0% | $417.5M | 43.2% | $83.5M | 8.6% |
| 2018 | $903.9M | +2.0% | $411.9M | 45.6% | $56.2M | 6.2% |
| 2017 | $886.1M | -2.5% | $378.5M | 42.7% | $-19,381,000 | -2.2% |
| 2016 | $908.8M | -0.2% | $405.9M | 44.7% | $-43,942,000 | -4.8% |
See HAE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs HAE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare HAE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonHAE — Frequently Asked Questions
Quick answers to the most common questions about buying HAE stock.
Is HAE's revenue growth accelerating or slowing?
HAE revenue growth slowed to -2.7%, below the 5-year CAGR of +6.6%. TTM revenue is $1.3B. The deceleration marks a shift from historical growth rates.
What is HAE's long-term revenue growth rate?
Haemonetics Corporation's 5-year revenue CAGR of +6.6% reflects the variable expansion pattern. Current YoY growth of -2.7% is near this long-term average.
How is HAE's revenue distributed by segment?
HAE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.